drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00661 | DB08870 | 122 | 850 | [
"DDInter1928",
"DDInter228"
] | Verapamil | Brentuximab vedotin | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
122,
24,
850
]
],
[
[
122,
24,
1033
],
[
1033,
63,
850
]
],
[
[
122,
62,
1512
],
[
1512,
24,
850
]
],
[
[
122,
63,
883
],
[
883,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Verapamil may cause a minor interaction that can limit clinical effects when taken with Diclofenac and Dic... |
DB00030 | DB14276 | 1,685 | 1,631 | [
"DDInter934",
"DDInter1892"
] | Insulin human | Turmeric | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Moderate | 1 | [
[
[
1685,
24,
1631
]
],
[
[
1685,
24,
1479
],
[
1479,
23,
1631
]
],
[
[
1685,
24,
1281
],
[
1281,
24,
1631
]
],
[
[
1685,
24,
1479
],
[
14... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Turmeric"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Turmeric
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with... |
DB08865 | DB08881 | 1,593 | 868 | [
"DDInter448",
"DDInter1925"
] | Crizotinib | Vemurafenib | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
1593,
25,
868
]
],
[
[
1593,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1593,
7,
7972
],
[
7972,
46,
868
]
],
[
[
1593,
18,
6123
],
[
6123,
... | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Crizotinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemura... | Crizotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Crizotinib (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Vemurafenib (Compound)
Crizotinib (Compound) downregulates PYCR1 (Gene) and PYCR1 (Gene) is upregulated by Vemurafenib (Compound)
Crizotini... |
DB00939 | DB01124 | 1,338 | 1,411 | [
"DDInter1135",
"DDInter1828"
] | Meclofenamic acid | Tolbutamide | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1338,
24,
1411
]
],
[
[
1338,
24,
959
],
[
959,
40,
1411
]
],
[
[
1338,
63,
245
],
[
245,
40,
1411
]
],
[
[
1338,
6,
10612
],
[
10612,... | [
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
... | Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbuta... |
DB01118 | DB05239 | 33 | 866 | [
"DDInter76",
"DDInter425"
] | Amiodarone | Cobimetinib | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
33,
24,
866
]
],
[
[
33,
24,
214
],
[
214,
63,
866
]
],
[
[
33,
64,
888
],
[
888,
24,
866
]
],
[
[
33,
63,
482
],
[
482,
24,
... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Amiodarone may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cau... |
DB00095 | DB06650 | 66 | 1,500 | [
"DDInter623",
"DDInter1324"
] | Efalizumab | Ofatumumab | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however... | Moderate | 1 | [
[
[
66,
24,
1500
]
],
[
[
66,
24,
270
],
[
270,
63,
1500
]
],
[
[
66,
24,
869
],
[
869,
24,
1500
]
],
[
[
66,
63,
1184
],
[
1184,
24... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topot... |
DB00489 | DB06704 | 17 | 247 | [
"DDInter1704",
"DDInter952"
] | Sotalol | Iobenguane (I-131) | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
17,
25,
247
]
],
[
[
17,
21,
28787
],
[
28787,
60,
247
]
],
[
[
17,
25,
820
],
[
820,
24,
247
]
],
[
[
17,
63,
999
],
[
999,
24,... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound... | Sotalol may lead to a major life threatening interaction when taken with Iobenguane
Sotalol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
Sotalol may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate... |
DB00656 | DB11113 | 827 | 657 | [
"DDInter1851",
"DDInter307"
] | Trazodone | Castor oil | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
827,
24,
657
]
],
[
[
827,
24,
927
],
[
927,
63,
657
]
],
[
[
827,
24,
1491
],
[
1491,
24,
657
]
],
[
[
827,
25,
985
],
[
985,
2... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midos... |
DB00801 | DB06691 | 1,563 | 849 | [
"DDInter850",
"DDInter1155"
] | Halazepam | Mepyramine | Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1563,
24,
849
]
],
[
[
1563,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1563,
24,
272
],
[
272,
24,
849
]
],
[
[
1563,
40,
1119
],
[
1119,
... | [
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Ch... |
DB00556 | DB11718 | 1,262 | 927 | [
"DDInter1429",
"DDInter640"
] | Perflutren | Encorafenib | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1262,
24,
927
]
],
[
[
1262,
23,
112
],
[
112,
23,
927
]
],
[
[
1262,
24,
720
],
[
720,
24,
927
]
],
[
[
1262,
63,
1010
],
[
1010,
... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Perflutren",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mi... |
DB08815 | DB08882 | 154 | 1,281 | [
"DDInter1104",
"DDInter1070"
] | Lurasidone | Linagliptin | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
154,
24,
1281
]
],
[
[
154,
63,
1002
],
[
1002,
1,
1281
]
],
[
[
154,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
154,
21,
29081
],
[
29081,
... | [
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Lurasidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Lurasidone (Compound) causes Angioedema (Side Effect) and Angioe... |
DB00622 | DB06791 | 1,081 | 1,446 | [
"DDInter1287",
"DDInter1021"
] | Nicardipine | Lanreotide | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Moderate | 1 | [
[
[
1081,
24,
1446
]
],
[
[
1081,
24,
1017
],
[
1017,
63,
1446
]
],
[
[
1081,
63,
1324
],
[
1324,
24,
1446
]
],
[
[
1081,
24,
549
],
[
549... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
... | Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Tr... |
DB00352 | DB08881 | 482 | 868 | [
"DDInter1814",
"DDInter1925"
] | Tioguanine | Vemurafenib | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
482,
24,
868
]
],
[
[
482,
21,
28658
],
[
28658,
60,
868
]
],
[
[
482,
24,
1247
],
[
1247,
23,
868
]
],
[
[
482,
63,
168
],
[
168,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is cause... | Tioguanine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Vemurafenib (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken wit... |
DB00841 | DB11827 | 532 | 433 | [
"DDInter577",
"DDInter669"
] | Dobutamine | Ertugliflozin | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
532,
24,
433
]
],
[
[
532,
24,
959
],
[
959,
24,
433
]
],
[
[
532,
1,
817
],
[
817,
24,
433
]
],
[
[
532,
63,
1466
],
[
1466,
24... | [
[
[
"Dobutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Dobutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Dobutamine (Compound) resembles Dopamine (Compound) and Dopamine may cause a moderate interaction that could ex... |
DB00819 | DB01105 | 471 | 222 | [
"DDInter15",
"DDInter1665"
] | Acetazolamide | Sibutramine | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
471,
24,
222
]
],
[
[
471,
6,
8374
],
[
8374,
45,
222
]
],
[
[
471,
21,
29152
],
[
29152,
60,
222
]
],
[
[
471,
24,
659
],
[
659,
... | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Acetazolamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Acetazolamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Acetazolamide (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Sibutramine (Compound)
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and... |
DB00888 | DB05273 | 1,001 | 507 | [
"DDInter1133",
"DDInter1638"
] | Mechlorethamine | Samarium (153Sm) lexidronam | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
1001,
25,
507
]
],
[
[
1001,
24,
248
],
[
248,
24,
507
]
],
[
[
1001,
24,
270
],
[
270,
63,
507
]
],
[
[
1001,
63,
970
],
[
970,
... | [
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"... | Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Mechlorethamine may cause a moderate interaction that could exacerbate diseases wh... |
DB00674 | DB00927 | 1,516 | 1,559 | [
"DDInter802",
"DDInter712"
] | Galantamine | Famotidine | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
1516,
24,
1559
]
],
[
[
1516,
21,
28729
],
[
28729,
60,
1559
]
],
[
[
1516,
24,
112
],
[
112,
23,
1559
]
],
[
[
1516,
24,
594
],
[
594... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Galantamine",
"{u} (Compound) causes {v} (Side Effect)",
"Pain in extremity"
],
[
"Pain in extremity",
"{u} (Si... | Galantamine (Compound) causes Pain in extremity (Side Effect) and Pain in extremity (Side Effect) is caused by Famotidine (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects w... |
DB01284 | DB04575 | 1,042 | 35 | [
"DDInter1782",
"DDInter1555"
] | Tetracosactide | Quinestrol | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | The 3-cyclopentyl ether of ethinyl estradiol. | Moderate | 1 | [
[
[
1042,
24,
35
]
],
[
[
1042,
24,
890
],
[
890,
1,
35
]
],
[
[
1042,
63,
559
],
[
559,
1,
35
]
],
[
[
1042,
24,
177
],
[
177,
40,
... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
],
... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol (Compound) resembles Quinestrol (Compound)
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Estrone and Estrone (Compound) resembles Quinestrol (Compound)
... |
DB00792 | DB01267 | 832 | 519 | [
"DDInter1878",
"DDInter1381"
] | Tripelennamine | Paliperidone | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
832,
24,
519
]
],
[
[
832,
63,
1664
],
[
1664,
1,
519
]
],
[
[
832,
24,
924
],
[
924,
1,
519
]
],
[
[
832,
6,
10104
],
[
10104,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone (Compound) resembles Paliperi... |
DB00841 | DB09564 | 532 | 1,296 | [
"DDInter577",
"DDInter930"
] | Dobutamine | Insulin degludec | A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
532,
24,
1296
]
],
[
[
532,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
532,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
532,
1,
1523
],
[
1523,
... | [
[
[
"Dobutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Dobutamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
... | Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and... |
DB00524 | DB13928 | 811 | 1,385 | [
"DDInter1199",
"DDInter1660"
] | Metolazone | Semaglutide | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
811,
24,
1385
]
],
[
[
811,
1,
359
],
[
359,
24,
1385
]
],
[
[
811,
24,
891
],
[
891,
24,
1385
]
],
[
[
811,
63,
1685
],
[
1685,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may cause ... | Metolazone (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interacti... |
DB01211 | DB14509 | 609 | 1,399 | [
"DDInter393",
"DDInter1081"
] | Clarithromycin | Lithium carbonate | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
609,
24,
1399
]
],
[
[
609,
24,
1385
],
[
1385,
24,
1399
]
],
[
[
609,
63,
1010
],
[
1010,
24,
1399
]
],
[
[
609,
25,
927
],
[
927,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Mefl... |
DB06207 | DB09112 | 910 | 1,455 | [
"DDInter1667",
"DDInter1306"
] | Silodosin | Nitrous acid | Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenocepto... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
910,
24,
1455
]
],
[
[
910,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
910,
24,
433
],
[
433,
63,
1455
]
],
[
[
910,
63,
274
],
[
274,
... | [
[
[
"Silodosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Silodosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[... | Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin a... |
DB00491 | DB00902 | 127 | 104 | [
"DDInter1217",
"DDInter1168"
] | Miglitol | Methdilazine | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
127,
24,
104
]
],
[
[
127,
24,
820
],
[
820,
1,
104
]
],
[
[
127,
63,
508
],
[
508,
1,
104
]
],
[
[
127,
24,
401
],
[
401,
63,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Methdilazine (Compound)
... |
DB00952 | DB01168 | 1,541 | 1,053 | [
"DDInter1267",
"DDInter1526"
] | Naratriptan | Procarbazine | Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
1541,
25,
1053
]
],
[
[
1541,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1541,
25,
1039
],
[
1039,
64,
1053
]
],
[
[
1541,
64,
1494
],
[
... | [
[
[
"Naratriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Naratriptan",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Co... | Naratriptan (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Naratriptan may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may lead to a major life threatening interaction when taken with Procarbazine
Naratriptan ... |
DB00912 | DB09046 | 473 | 1,094 | [
"DDInter1581",
"DDInter1201"
] | Repaglinide | Metreleptin | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Moderate | 1 | [
[
[
473,
24,
1094
]
],
[
[
473,
24,
1612
],
[
1612,
62,
1094
]
],
[
[
473,
63,
168
],
[
168,
23,
1094
]
],
[
[
473,
24,
861
],
[
861,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Metreleptin
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bor... |
DB05316 | DB11837 | 749 | 1,297 | [
"DDInter1467",
"DDInter1351"
] | Pimavanserin | Osilodrostat | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
749,
24,
1297
]
],
[
[
749,
62,
112
],
[
112,
23,
1297
]
],
[
[
749,
24,
1320
],
[
1320,
63,
1297
]
],
[
[
749,
63,
353
],
[
353,
... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Pimavanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and ... |
DB01159 | DB01268 | 419 | 1,151 | [
"DDInter854",
"DDInter1731"
] | Halothane | Sunitinib | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
419,
24,
1151
]
],
[
[
419,
6,
8374
],
[
8374,
45,
1151
]
],
[
[
419,
62,
112
],
[
112,
23,
1151
]
],
[
[
419,
63,
1148
],
[
1148,
... | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Halothane",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Halothane (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sunitinib
Halothane may cause ... |
DB00344 | DB00388 | 1,302 | 1,636 | [
"DDInter1543",
"DDInter1453"
] | Protriptyline | Phenylephrine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Major | 2 | [
[
[
1302,
25,
1636
]
],
[
[
1302,
25,
874
],
[
874,
40,
1636
]
],
[
[
1302,
24,
1148
],
[
1148,
63,
1636
]
],
[
[
1302,
21,
28956
],
[
289... | [
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylephrine"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
... | Protriptyline may lead to a major life threatening interaction when taken with Epinephrine and Epinephrine (Compound) resembles Phenylephrine (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could... |
DB00526 | DB09268 | 1,555 | 1,662 | [
"DDInter1355",
"DDInter1464"
] | Oxaliplatin | Picosulfuric acid | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1555,
24,
1662
]
],
[
[
1555,
24,
1164
],
[
1164,
24,
1662
]
],
[
[
1555,
24,
484
],
[
484,
63,
1662
]
],
[
[
1555,
25,
1618
],
[
1618... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Entrecti... |
DB00279 | DB01203 | 1,152 | 699 | [
"DDInter1074",
"DDInter1255"
] | Liothyronine | Nadolol | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Minor | 0 | [
[
[
1152,
23,
699
]
],
[
[
1152,
23,
729
],
[
729,
1,
699
]
],
[
[
1152,
6,
4973
],
[
4973,
45,
699
]
],
[
[
1152,
21,
28882
],
[
28882,
... | [
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nadolol"
]
],
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Penbutolol"
],
[
... | Liothyronine may cause a minor interaction that can limit clinical effects when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Liothyronine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nadolol (Compound)
Liothyronine (Compound) causes Body temperature increased (Side Effect) ... |
DB00867 | DB05812 | 1,052 | 1,374 | [
"DDInter1606",
"DDInter8"
] | Ritodrine | Abiraterone | Adrenergic beta-agonist used to control premature labor. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
1052,
24,
1374
]
],
[
[
1052,
63,
1494
],
[
1494,
24,
1374
]
],
[
[
1052,
24,
1133
],
[
1133,
24,
1374
]
],
[
[
1052,
24,
594
],
[
594... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],
[
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Gr... |
DB00574 | DB08896 | 121 | 292 | [
"DDInter717",
"DDInter1576"
] | Fenfluramine | Regorafenib | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
121,
24,
292
]
],
[
[
121,
24,
549
],
[
549,
23,
292
]
],
[
[
121,
25,
643
],
[
643,
24,
292
]
],
[
[
121,
64,
109
],
[
109,
24,... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Regorafenib
Fenfluramine may lead to a major life threatening interaction when taken with Desvenlafaxine and Desvenla... |
DB01403 | DB09038 | 9 | 1,450 | [
"DDInter1175",
"DDInter636"
] | Methotrimeprazine | Empagliflozin | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
9,
24,
1450
]
],
[
[
9,
63,
485
],
[
485,
24,
1450
]
],
[
[
9,
24,
659
],
[
659,
63,
1450
]
],
[
[
9,
1,
104
],
[
104,
24,
... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidin... | Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Vi... |
DB01174 | DB12141 | 697 | 971 | [
"DDInter1442",
"DDInter817"
] | Phenobarbital | Gilteritinib | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
697,
24,
971
]
],
[
[
697,
25,
1135
],
[
1135,
23,
971
]
],
[
[
697,
25,
466
],
[
466,
62,
971
]
],
[
[
697,
63,
112
],
[
112,
2... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Nal... | Phenobarbital may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Phenobarbital may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor... |
DB01069 | DB09034 | 401 | 1,313 | [
"DDInter1533",
"DDInter1733"
] | Promethazine | Suvorexant | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
401,
24,
1313
]
],
[
[
401,
24,
649
],
[
649,
24,
1313
]
],
[
[
401,
24,
1619
],
[
1619,
63,
1313
]
],
[
[
401,
63,
530
],
[
530,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Ruc... |
DB00348 | DB11901 | 254 | 913 | [
"DDInter1300",
"DDInter107"
] | Nitisinone | Apalutamide | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
254,
24,
913
]
],
[
[
254,
24,
1247
],
[
1247,
23,
913
]
],
[
[
254,
63,
600
],
[
600,
24,
913
]
],
[
[
254,
24,
609
],
[
609,
2... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazol... |
DB00358 | DB00370 | 1,010 | 1,251 | [
"DDInter1140",
"DDInter1230"
] | Mefloquine | Mirtazapine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Moderate | 1 | [
[
[
1010,
24,
1251
]
],
[
[
1010,
6,
12523
],
[
12523,
45,
1251
]
],
[
[
1010,
21,
28680
],
[
28680,
60,
1251
]
],
[
[
1010,
23,
112
],
[
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)"... | Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mirtazapine (Compound)
Mefloquine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Mirtazapine (Compound)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazo... |
DB00047 | DB00951 | 176 | 1,072 | [
"DDInter932",
"DDInter986"
] | Insulin glargine | Isoniazid | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Moderate | 1 | [
[
[
176,
24,
1072
]
],
[
[
176,
24,
1486
],
[
1486,
62,
1072
]
],
[
[
176,
24,
870
],
[
870,
23,
1072
]
],
[
[
176,
24,
1130
],
[
1130,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolo... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Isoniazid
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00491 | DB09278 | 127 | 852 | [
"DDInter1217",
"DDInter24"
] | Miglitol | Activated charcoal | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity... | Moderate | 1 | [
[
[
127,
24,
852
]
],
[
[
127,
24,
1411
],
[
1411,
24,
852
]
],
[
[
127,
63,
590
],
[
590,
24,
852
]
],
[
[
127,
24,
1411
],
[
1411,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide a... |
DB00552 | DB15965 | 1,238 | 1,330 | [
"DDInter1425",
"DDInter1270"
] | Pentostatin | Naxitamab | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
1238,
24,
1330
]
],
[
[
1238,
24,
1532
],
[
1532,
24,
1330
]
],
[
[
1238,
63,
597
],
[
597,
24,
1330
]
],
[
[
1238,
25,
770
],
[
770,
... | [
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
... | Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and ... |
DB08827 | DB09065 | 990 | 760 | [
"DDInter1085",
"DDInter424"
] | Lomitapide | Cobicistat | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
990,
25,
760
]
],
[
[
990,
64,
1101
],
[
1101,
23,
760
]
],
[
[
990,
64,
1195
],
[
1195,
24,
760
]
],
[
[
990,
25,
868
],
[
868,
... | [
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} m... | Lomitapide may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Lomitapide may lead to a major life threatening interaction when taken with Erlotinib and Erlotinib may cause a moderate interact... |
DB01018 | DB08895 | 1,364 | 976 | [
"DDInter847",
"DDInter1825"
] | Guanfacine | Tofacitinib | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
1364,
24,
976
]
],
[
[
1364,
24,
214
],
[
214,
63,
976
]
],
[
[
1364,
25,
1017
],
[
1017,
63,
976
]
],
[
[
1364,
24,
86
],
[
86,
... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[... | Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Guanfacine may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may c... |
DB00991 | DB06605 | 97 | 1,409 | [
"DDInter1358",
"DDInter108"
] | Oxaprozin | Apixaban | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
97,
25,
1409
]
],
[
[
97,
6,
6017
],
[
6017,
45,
1409
]
],
[
[
97,
21,
29666
],
[
29666,
60,
1409
]
],
[
[
97,
40,
307
],
[
307,
... | [
[
[
"Oxaprozin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Oxaprozin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"
... | Oxaprozin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Apixaban (Compound)
Oxaprozin (Compound) causes Melaena (Side Effect) and Melaena (Side Effect) is caused by Apixaban (Compound)
Oxaprozin (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical ... |
DB00468 | DB09098 | 1,424 | 98 | [
"DDInter1557",
"DDInter1700"
] | Quinine | Somatrem | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1424,
24,
98
]
],
[
[
1424,
24,
1612
],
[
1612,
62,
98
]
],
[
[
1424,
24,
159
],
[
159,
63,
98
]
],
[
[
1424,
25,
11
],
[
11,
24... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fo... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectin... |
DB00108 | DB01024 | 1,066 | 1,096 | [
"DDInter1268",
"DDInter1252"
] | Natalizumab | Mycophenolic acid | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Major | 2 | [
[
[
1066,
25,
1096
]
],
[
[
1066,
25,
955
],
[
955,
1,
1096
]
],
[
[
1066,
23,
1193
],
[
1193,
62,
1096
]
],
[
[
1066,
23,
1461
],
[
1461,... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolate mofetil"
],
[
"Mycop... | Natalizumab may lead to a major life threatening interaction when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor int... |
DB00404 | DB09036 | 523 | 812 | [
"DDInter54",
"DDInter1668"
] | Alprazolam | Siltuximab | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
523,
24,
812
]
],
[
[
523,
62,
1031
],
[
1031,
24,
812
]
],
[
[
523,
63,
608
],
[
608,
24,
812
]
],
[
[
523,
1,
1565
],
[
1565,
... | [
[
[
"Alprazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
... | Alprazolam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidoc... |
DB00582 | DB09030 | 1,622 | 840 | [
"DDInter1946",
"DDInter1945"
] | Voriconazole | Vorapaxar | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
1622,
25,
840
]
],
[
[
1622,
25,
1017
],
[
1017,
63,
840
]
],
[
[
1622,
25,
578
],
[
578,
24,
840
]
],
[
[
1622,
24,
98
],
[
98,
... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u... | Voriconazole may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Voriconazole may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate i... |
DB01076 | DB12267 | 700 | 1,476 | [
"DDInter133",
"DDInter233"
] | Atorvastatin | Brigatinib | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
700,
24,
1476
]
],
[
[
700,
63,
168
],
[
168,
23,
1476
]
],
[
[
700,
63,
629
],
[
629,
24,
1476
]
],
[
[
700,
24,
951
],
[
951,
... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirol... |
DB00397 | DB01253 | 1,466 | 628 | [
"DDInter1458",
"DDInter664"
] | Phenylpropanolamine | Ergometrine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Major | 2 | [
[
[
1466,
25,
628
]
],
[
[
1466,
64,
1131
],
[
1131,
40,
628
]
],
[
[
1466,
25,
469
],
[
469,
40,
628
]
],
[
[
1466,
6,
5214
],
[
5214,
... | [
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ergometrine"
]
],
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methysergide"
],
[
"Meth... | Phenylpropanolamine may lead to a major life threatening interaction when taken with Methysergide and Methysergide (Compound) resembles Ergometrine (Compound)
Phenylpropanolamine may lead to a major life threatening interaction when taken with Bromocriptine and Bromocriptine (Compound) resembles Ergometrine (Compound)
... |
DB01599 | DB06616 | 1,232 | 594 | [
"DDInter1523",
"DDInter224"
] | Probucol | Bosutinib | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
1232,
24,
594
]
],
[
[
1232,
62,
112
],
[
112,
23,
594
]
],
[
[
1232,
63,
1559
],
[
1559,
24,
594
]
],
[
[
1232,
24,
1374
],
[
1374,
... | [
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Probucol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Probucol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidin... |
DB09135 | DB14600 | 1,211 | 224 | [
"DDInter967",
"DDInter620"
] | Ioxilan | Edetate disodium anhydrous | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Edetate disodium anhydrous is a polyvalent chelating agent used to treat hypercalcemia and digitalis toxicity associated ventricular arrhythmias. | Major | 2 | [
[
[
1211,
25,
224
]
],
[
[
1211,
64,
372
],
[
372,
24,
224
]
],
[
[
1211,
64,
789
],
[
789,
24,
372
],
[
372,
24,
224
]
],
[
[
1211,
... | [
[
[
"Ioxilan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edetate disodium anhydrous"
]
],
[
[
"Ioxilan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
... | Ioxilan may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Edetate disodium anhydrous
Ioxilan may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may cause a mod... |
DB01254 | DB06723 | 1,213 | 115 | [
"DDInter484",
"DDInter58"
] | Dasatinib | Aluminum hydroxide | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
1213,
24,
115
]
],
[
[
1213,
21,
28643
],
[
28643,
60,
115
]
],
[
[
1213,
63,
870
],
[
870,
23,
115
]
],
[
[
1213,
64,
1018
],
[
1018,... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Dasatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) i... | Dasatinib (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Aluminum hydroxide (Compound)
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when take... |
DB01097 | DB01265 | 1,377 | 1,477 | [
"DDInter1033",
"DDInter1757"
] | Leflunomide | Telbivudine | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Moderate | 1 | [
[
[
1377,
24,
1477
]
],
[
[
1377,
64,
1083
],
[
1083,
1,
1477
]
],
[
[
1377,
21,
28745
],
[
28745,
60,
1477
]
],
[
[
1377,
64,
1142
],
[
1... | [
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifl... | Leflunomide may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine (Compound) resembles Telbivudine (Compound)
Leflunomide (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Telbivudine (Compound)
Leflunomide may lead to a m... |
DB00317 | DB08899 | 883 | 129 | [
"DDInter810",
"DDInter649"
] | Gefitinib | Enzalutamide | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
883,
24,
129
]
],
[
[
883,
24,
918
],
[
918,
1,
129
]
],
[
[
883,
6,
8374
],
[
8374,
45,
129
]
],
[
[
883,
21,
28703
],
[
28703,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Gefitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Gefitinib (Compound) causes Pruritus (Side Effect) and Pruri... |
DB00884 | DB09407 | 1,008 | 853 | [
"DDInter1604",
"DDInter1114"
] | Risedronic acid | Magnesium chloride | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
1008,
24,
853
]
],
[
[
1008,
63,
544
],
[
544,
24,
853
]
],
[
[
1008,
24,
460
],
[
460,
63,
853
]
],
[
[
1008,
40,
1485
],
[
1485,
... | [
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium... | Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Risedronic acid may cause a moderate interaction that could exacerbate diseases when ... |
DB00460 | DB01246 | 612 | 820 | [
"DDInter1929",
"DDInter45"
] | Verteporfin | Alimemazine | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
612,
24,
820
]
],
[
[
612,
24,
104
],
[
104,
40,
820
]
],
[
[
612,
24,
401
],
[
401,
24,
820
]
],
[
[
612,
21,
28666
],
[
28666,
... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction... |
DB00704 | DB11952 | 267 | 800 | [
"DDInter1263",
"DDInter612"
] | Naltrexone | Duvelisib | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
267,
24,
800
]
],
[
[
267,
63,
467
],
[
467,
24,
800
]
],
[
[
267,
24,
1496
],
[
1496,
24,
800
]
],
[
[
267,
24,
564
],
[
564,
6... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Ninte... |
DB00457 | DB00635 | 1,205 | 1,573 | [
"DDInter1511",
"DDInter1515"
] | Prazosin | Prednisone | Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTS... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
1205,
24,
1573
]
],
[
[
1205,
24,
175
],
[
175,
40,
1573
]
],
[
[
1205,
63,
251
],
[
251,
1,
1573
]
],
[
[
1205,
24,
167
],
[
167,
... | [
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
... | Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (Co... |
DB01018 | DB01285 | 1,364 | 708 | [
"DDInter847",
"DDInter445"
] | Guanfacine | Corticotropin | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
1364,
24,
708
]
],
[
[
1364,
40,
390
],
[
390,
24,
708
]
],
[
[
1364,
63,
1324
],
[
1324,
24,
708
]
],
[
[
1364,
24,
1450
],
[
1450,
... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Guanfacine",
"{u} (Compound) resembles {v} (Compound)",
"Guanabenz"
],
[
"Guanabenz",
"{u} may cause a modera... | Guanfacine (Compound) resembles Guanabenz (Compound) and Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that ... |
DB00218 | DB14491 | 1,176 | 428 | [
"DDInter1247",
"DDInter725"
] | Moxifloxacin | Ferrous fumarate | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
1176,
24,
428
]
],
[
[
1176,
24,
1096
],
[
1096,
23,
428
]
],
[
[
1176,
1,
246
],
[
246,
24,
428
]
],
[
[
1176,
24,
1384
],
[
1384,
... | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid... | Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Moxifloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moder... |
DB00570 | DB09291 | 147 | 741 | [
"DDInter1936",
"DDInter1615"
] | Vinblastine | Rolapitant | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
147,
24,
741
]
],
[
[
147,
24,
159
],
[
159,
63,
741
]
],
[
[
147,
24,
1671
],
[
1671,
24,
741
]
],
[
[
147,
63,
353
],
[
353,
2... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin a... |
DB00758 | DB10344 | 1,347 | 992 | [
"DDInter413",
"DDInter818"
] | Clopidogrel | Ginger | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Ginger allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
1347,
24,
992
]
],
[
[
1347,
64,
1578
],
[
1578,
24,
992
]
],
[
[
1347,
25,
1421
],
[
1421,
63,
992
]
],
[
[
1347,
63,
1167
],
[
1167,... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginger"
]
],
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
... | Clopidogrel may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ginger
Clopidogrel may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interact... |
DB00867 | DB00927 | 1,052 | 1,559 | [
"DDInter1606",
"DDInter712"
] | Ritodrine | Famotidine | Adrenergic beta-agonist used to control premature labor. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
1052,
24,
1559
]
],
[
[
1052,
24,
594
],
[
594,
63,
1559
]
],
[
[
1052,
25,
478
],
[
478,
63,
1559
]
],
[
[
1052,
63,
1494
],
[
1494,
... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Ritodrine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a mode... |
DB04946 | DB08881 | 924 | 868 | [
"DDInter907",
"DDInter1925"
] | Iloperidone | Vemurafenib | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
924,
25,
868
]
],
[
[
924,
6,
8374
],
[
8374,
45,
868
]
],
[
[
924,
18,
4046
],
[
4046,
46,
868
]
],
[
[
924,
21,
28847
],
[
28847,
... | [
[
[
"Iloperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Iloperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemu... | Iloperidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Iloperidone (Compound) downregulates PIK3C2B (Gene) and PIK3C2B (Gene) is upregulated by Vemurafenib (Compound)
Iloperidone (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib... |
DB00381 | DB01246 | 376 | 820 | [
"DDInter79",
"DDInter45"
] | Amlodipine | Alimemazine | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
376,
24,
820
]
],
[
[
376,
24,
104
],
[
104,
40,
820
]
],
[
[
376,
24,
401
],
[
401,
24,
820
]
],
[
[
376,
6,
8374
],
[
8374,
45... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction t... |
DB01242 | DB06699 | 1,237 | 774 | [
"DDInter410",
"DDInter493"
] | Clomipramine | Degarelix | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
1237,
24,
774
]
],
[
[
1237,
63,
521
],
[
521,
1,
774
]
],
[
[
1237,
21,
29232
],
[
29232,
60,
774
]
],
[
[
1237,
62,
112
],
[
112,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Clomipramine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Clomipramine may cause a minor interaction t... |
DB00242 | DB10316 | 1,064 | 334 | [
"DDInter392",
"DDInter1248"
] | Cladribine | Mumps virus strain B level jeryl lynn live antigen | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
1064,
25,
334
]
],
[
[
1064,
25,
1042
],
[
1042,
24,
334
]
],
[
[
1064,
25,
594
],
[
594,
25,
334
]
],
[
[
1064,
64,
1057
],
[
1057,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
... | Cladribine may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Cladribine may lead to a major life threatening interaction when taken with Bos... |
DB00916 | DB12825 | 112 | 1,375 | [
"DDInter1202",
"DDInter1032"
] | Metronidazole | Lefamulin | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Minor | 0 | [
[
[
112,
23,
1375
]
],
[
[
112,
24,
309
],
[
309,
24,
1375
]
],
[
[
112,
23,
688
],
[
688,
24,
1375
]
],
[
[
112,
63,
450
],
[
450,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lefamulin"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
... | Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Salbutamol and S... |
DB00910 | DB13179 | 1,041 | 68 | [
"DDInter1394",
"DDInter1882"
] | Paricalcitol | Troleandomycin | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | A macrolide antibiotic that is similar to erythromycin. | Moderate | 1 | [
[
[
1041,
24,
68
]
],
[
[
1041,
24,
1619
],
[
1619,
24,
68
]
],
[
[
1041,
24,
351
],
[
351,
25,
68
]
],
[
[
1041,
24,
159
],
[
159,
... | [
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
... | Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and ... |
DB01032 | DB11817 | 824 | 1,259 | [
"DDInter1522",
"DDInter165"
] | Probenecid | Baricitinib | The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
824,
25,
1259
]
],
[
[
824,
62,
1274
],
[
1274,
24,
1259
]
],
[
[
824,
63,
1479
],
[
1479,
24,
1259
]
],
[
[
824,
23,
848
],
[
848,
... | [
[
[
"Probenecid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Probenecid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flurbiprofen"
],
[
"Flurbipro... | Probenecid may cause a minor interaction that can limit clinical effects when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic ac... |
DB05812 | DB09272 | 1,374 | 412 | [
"DDInter8",
"DDInter632"
] | Abiraterone | Eluxadoline | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1374,
24,
412
]
],
[
[
1374,
23,
74
],
[
74,
24,
412
]
],
[
[
1374,
63,
1131
],
[
1131,
24,
412
]
],
[
[
1374,
62,
441
],
[
441,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Boceprevir"
],
[
... | Abiraterone may cause a minor interaction that can limit clinical effects when taken with Boceprevir and Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Methysergide and Met... |
DB12301 | DB14568 | 907 | 982 | [
"DDInter585",
"DDInter1000"
] | Doravirine | Ivosidenib | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
907,
24,
982
]
],
[
[
907,
63,
1101
],
[
1101,
23,
982
]
],
[
[
907,
62,
1478
],
[
1478,
24,
982
]
],
[
[
907,
63,
1033
],
[
1033,
... | [
[
[
"Doravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Doravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Doravirine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Doravirine may cause a minor interaction that can limit clinical effects when taken with Ivacaftor and Ivacaftor m... |
DB00060 | DB00352 | 912 | 482 | [
"DDInter947",
"DDInter1814"
] | Interferon beta-1a | Tioguanine | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Moderate | 1 | [
[
[
912,
24,
482
]
],
[
[
912,
24,
1299
],
[
1299,
62,
482
]
],
[
[
912,
24,
1523
],
[
1523,
63,
482
]
],
[
[
912,
24,
1324
],
[
1324,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trovafloxac... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Tioguanine
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with L... |
DB00208 | DB10897 | 1,018 | 539 | [
"DDInter1804",
"DDInter291"
] | Ticlopidine | Capsicum | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Capsicum (Chili pepper) allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
1018,
23,
539
]
],
[
[
1018,
24,
885
],
[
885,
23,
539
]
],
[
[
1018,
25,
1226
],
[
1226,
23,
539
]
],
[
[
1018,
63,
582
],
[
582,
... | [
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
... | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ticlopidine may lead to a major life threatening interaction when taken with Tirofiban and Tirofiban may cause ... |
DB09481 | DB13257 | 460 | 260 | [
"DDInter1113",
"DDInter727"
] | Magnesium carbonate | Ferrous sulfate anhydrous | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age. This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells. Ferrous sulfate is a sy... | Moderate | 1 | [
[
[
460,
24,
260
]
],
[
[
460,
62,
752
],
[
752,
23,
260
]
],
[
[
460,
63,
1096
],
[
1096,
23,
260
]
],
[
[
460,
63,
1620
],
[
1620,
... | [
[
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Magnesium carbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
... | Magnesium carbonate may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ferrous sulfate anhydrous
Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when tak... |
DB00078 | DB03404 | 1,172 | 765 | [
"DDInter898",
"DDInter855"
] | Ibritumomab tiuxetan | Hemin | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Moderate | 1 | [
[
[
1172,
24,
765
]
],
[
[
1172,
25,
840
],
[
840,
63,
765
]
],
[
[
1172,
25,
291
],
[
291,
24,
765
]
],
[
[
1172,
64,
1578
],
[
1578,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
... | Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause a ... |
DB01227 | DB11130 | 1,301 | 407 | [
"DDInter1043",
"DDInter1344"
] | Levacetylmethadol | Opium | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1301,
24,
407
]
],
[
[
1301,
63,
662
],
[
662,
24,
407
]
],
[
[
1301,
24,
1054
],
[
1054,
24,
407
]
],
[
[
1301,
25,
849
],
[
849,
... | [
[
[
"Levacetylmethadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Levacetylmethadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
... | Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Kaolin... |
DB00675 | DB01177 | 888 | 77 | [
"DDInter1744",
"DDInter904"
] | Tamoxifen | Idarubicin | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
888,
24,
77
]
],
[
[
888,
5,
11579
],
[
11579,
44,
77
]
],
[
[
888,
6,
6017
],
[
6017,
45,
77
]
],
[
[
888,
7,
6952
],
[
6952,
4... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Tamoxifen",
"{u} (Compound) treats {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is treate... | Tamoxifen (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Idarubicin (Compound)
Tamoxifen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Tamoxifen (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Idarubicin (Compound)
Tamoxi... |
DB00661 | DB01229 | 122 | 973 | [
"DDInter1928",
"DDInter1378"
] | Verapamil | Paclitaxel (protein-bound) | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
122,
24,
973
]
],
[
[
122,
24,
310
],
[
310,
63,
973
]
],
[
[
122,
6,
7524
],
[
7524,
45,
973
]
],
[
[
122,
7,
6952
],
[
6952,
4... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Verapamil ... |
DB00344 | DB01075 | 1,302 | 1,376 | [
"DDInter1543",
"DDInter569"
] | Protriptyline | Diphenhydramine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
1302,
24,
1376
]
],
[
[
1302,
24,
649
],
[
649,
63,
1376
]
],
[
[
1302,
25,
11
],
[
11,
1,
1376
]
],
[
[
1302,
24,
128
],
[
128,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Protriptyline may lead to a major life threatening interaction when taken with Toremifene and Toremifene... |
DB01105 | DB01221 | 222 | 1,190 | [
"DDInter1665",
"DDInter1007"
] | Sibutramine | Ketamine | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Moderate | 1 | [
[
[
222,
24,
1190
]
],
[
[
222,
6,
8374
],
[
8374,
45,
1190
]
],
[
[
222,
21,
28642
],
[
28642,
60,
1190
]
],
[
[
222,
24,
649
],
[
649,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Sibutramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ketamine (Compound)
Sibutramine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Ketamine (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol ma... |
DB01041 | DB01242 | 770 | 1,237 | [
"DDInter1789",
"DDInter410"
] | Thalidomide | Clomipramine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
770,
24,
1237
]
],
[
[
770,
63,
684
],
[
684,
1,
1237
]
],
[
[
770,
63,
902
],
[
902,
40,
1237
]
],
[
[
770,
24,
272
],
[
272,
2... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Clomipramine (Comp... |
DB01010 | DB01148 | 61 | 1,128 | [
"DDInter622",
"DDInter738"
] | Edrophonium | Flavoxate | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Moderate | 1 | [
[
[
61,
24,
1128
]
],
[
[
61,
21,
28658
],
[
28658,
60,
1128
]
],
[
[
61,
63,
1123
],
[
1123,
24,
1128
]
],
[
[
61,
24,
1511
],
[
1511,
... | [
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flavoxate"
]
],
[
[
"Edrophonium",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is cause... | Edrophonium (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Flavoxate (Compound)
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Fl... |
DB00041 | DB01324 | 1,648 | 178 | [
"DDInter38",
"DDInter1490"
] | Aldesleukin | Polythiazide | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
1648,
24,
178
]
],
[
[
1648,
24,
674
],
[
674,
40,
178
]
],
[
[
1648,
24,
258
],
[
258,
24,
178
]
],
[
[
1648,
24,
1527
],
[
1527,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol and Iodixanol may cause a moderate inte... |
DB08901 | DB14783 | 1,468 | 287 | [
"DDInter1492",
"DDInter574"
] | Ponatinib | Diroximel fumarate | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1468,
24,
287
]
],
[
[
1468,
64,
1101
],
[
1101,
24,
287
]
],
[
[
1468,
63,
1560
],
[
1560,
24,
287
]
],
[
[
1468,
24,
384
],
[
384,
... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexa... | Ponatinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase ... |
DB08901 | DB14409 | 1,468 | 1,129 | [
"DDInter1492",
"DDInter867"
] | Ponatinib | Human adenovirus e serotype 4 strain cl-68578 antigen | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1468,
24,
1129
]
],
[
[
1468,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1468,
63,
1683
],
[
1683,
24,
1129
]
],
[
[
1468,
25,
1456
],
[
14... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"E... | Ponatinib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00092 | DB08885 | 58 | 363 | [
"DDInter40",
"DDInter33"
] | Alefacept | Aflibercept | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Moderate | 1 | [
[
[
58,
24,
363
]
],
[
[
58,
24,
1531
],
[
1531,
24,
363
]
],
[
[
58,
24,
151
],
[
151,
63,
363
]
],
[
[
58,
63,
1184
],
[
1184,
24,... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aflibercept"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/... |
DB00889 | DB13139 | 1,133 | 1,032 | [
"DDInter840",
"DDInter1063"
] | Granisetron | Levosalbutamol | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1133,
24,
1032
]
],
[
[
1133,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
1133,
24,
124
],
[
124,
24,
1032
]
],
[
[
1133,
64,
121
],
[
121,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Ca... | Granisetron may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib ma... |
DB00231 | DB00792 | 1,174 | 832 | [
"DDInter1761",
"DDInter1878"
] | Temazepam | Tripelennamine | Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175207, A175210, F3718, F3721]. Although the chem... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1174,
24,
832
]
],
[
[
1174,
24,
100
],
[
100,
63,
832
]
],
[
[
1174,
24,
649
],
[
649,
1,
832
]
],
[
[
1174,
24,
1594
],
[
1594,
... | [
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
... | Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Clofedano... |
DB00531 | DB10583 | 450 | 949 | [
"DDInter456",
"DDInter415"
] | Cyclophosphamide | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
450,
24,
949
]
],
[
[
450,
63,
589
],
[
589,
24,
949
]
],
[
[
450,
25,
1377
],
[
1377,
24,
949
]
],
[
[
450,
24,
970
],
[
970,
2... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate dis... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Cyclophosphamide may lead to a major life threatening inte... |
DB00514 | DB09128 | 506 | 1,241 | [
"DDInter527",
"DDInter231"
] | Dextromethorphan | Brexpiprazole | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
506,
24,
1241
]
],
[
[
506,
24,
741
],
[
741,
63,
1241
]
],
[
[
506,
24,
832
],
[
832,
24,
1241
]
],
[
[
506,
63,
1233
],
[
1233,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Tripel... |
DB00222 | DB08938 | 245 | 1,384 | [
"DDInter825",
"DDInter1112"
] | Glimepiride | Magaldrate | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
245,
24,
1384
]
],
[
[
245,
24,
167
],
[
167,
23,
1384
]
],
[
[
245,
24,
1529
],
[
1529,
24,
1384
]
],
[
[
245,
25,
246
],
[
246,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine... |
DB00500 | DB06441 | 24 | 936 | [
"DDInter1831",
"DDInter283"
] | Tolmetin | Cangrelor | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Moderate | 1 | [
[
[
24,
24,
936
]
],
[
[
24,
24,
477
],
[
477,
24,
936
]
],
[
[
24,
1,
831
],
[
831,
24,
936
]
],
[
[
24,
63,
305
],
[
305,
24,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Tolmetin (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could ... |
DB00197 | DB00304 | 1,324 | 1,657 | [
"DDInter1881",
"DDInter508"
] | Troglitazone | Desogestrel | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Desogestrel, a prodrug, is a third generation progestogen and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activ... | Moderate | 1 | [
[
[
1324,
24,
1657
]
],
[
[
1324,
24,
566
],
[
566,
40,
1657
]
],
[
[
1324,
24,
890
],
[
890,
1,
1657
]
],
[
[
1324,
24,
761
],
[
761,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desogestrel"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
],... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Desogestrel (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol (Compound) resembles Desogestrel... |
DB00620 | DB14730 | 175 | 1,412 | [
"DDInter1855",
"DDInter264"
] | Triamcinolone | Calaspargase pegol | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
175,
24,
1412
]
],
[
[
175,
24,
1439
],
[
1439,
24,
1412
]
],
[
[
175,
63,
1647
],
[
1647,
24,
1412
]
],
[
[
175,
40,
251
],
[
251,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Acarbos... |
DB00011 | DB00361 | 1,451 | 134 | [
"DDInter944",
"DDInter1939"
] | Interferon alfa-n1 | Vinorelbine | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC . It is a third-generation vinca alkaloid. The introduction of third... | Moderate | 1 | [
[
[
1451,
24,
134
]
],
[
[
1451,
24,
147
],
[
147,
63,
134
]
],
[
[
1451,
25,
1101
],
[
1101,
24,
134
]
],
[
[
1451,
24,
599
],
[
599,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastin... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Bexarotene and Be... |
DB04575 | DB08881 | 35 | 868 | [
"DDInter1555",
"DDInter1925"
] | Quinestrol | Vemurafenib | The 3-cyclopentyl ether of ethinyl estradiol. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
35,
24,
868
]
],
[
[
35,
24,
1040
],
[
1040,
63,
868
]
],
[
[
35,
40,
566
],
[
566,
24,
868
]
],
[
[
35,
63,
126
],
[
126,
24,
... | [
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
... | Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Quinestrol (Compound) resembles Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction t... |
DB00845 | DB00916 | 1,490 | 112 | [
"DDInter406",
"DDInter1202"
] | Clofazimine | Metronidazole | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Minor | 0 | [
[
[
1490,
23,
112
]
],
[
[
1490,
6,
8374
],
[
8374,
45,
112
]
],
[
[
1490,
21,
28640
],
[
28640,
60,
112
]
],
[
[
1490,
63,
618
],
[
618,
... | [
[
[
"Clofazimine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Clofazimine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Clofazimine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound)
Clofazimine (Compound) causes Depression (Side Effect) and Depression (Side Effect) is caused by Metronidazole (Compound)
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix... |
DB00601 | DB01069 | 453 | 401 | [
"DDInter1073",
"DDInter1533"
] | Linezolid | Promethazine | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
453,
24,
401
]
],
[
[
453,
25,
1264
],
[
1264,
63,
401
]
],
[
[
453,
24,
820
],
[
820,
63,
401
]
],
[
[
453,
24,
104
],
[
104,
2... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
... | Linezolid may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a mo... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.